- Published on
KembaraXtra-Medicine – Autoimmune Hemolytic Anemia
Autoimmune hemolytic anemia (AIHA) is a condition in which autoantibodies and/or complement bind to red blood cells (RBCs), leading to their premature destruction. About half of cases are primary (idiopathic), while the rest are secondary to underlying diseases or drugs. AIHA is commonly categorized into warm antibody–mediated disease (usually IgG, reacting best at 37°C), cold antibody–mediated disease (typically IgM with complement), and drug-induced immune hemolysis.
AIHA is uncommon, with an annual incidence of about 1 to 3 cases per 100,000 people and an estimated mortality around 10%. It is reported more often in women younger than 50 years. Patients most commonly present with fatigue and dyspnea. Pallor and jaundice may be present, and tachycardia with a flow murmur can occur when anemia is significant. Intravascular hemolysis may cause dark urine and back pain. Hepatomegaly or lymphadenopathy suggests a lymphoproliferative disorder or malignancy, while splenomegaly may suggest hypersplenism. The course is often chronic with relapses.
Warm AIHA is usually mediated by IgG antibodies and may be idiopathic or associated with leukemia/lymphoma, thymoma, myeloma, viral infections, babesiosis, and collagen-vascular diseases. Cold AIHA is commonly IgM- and complement-mediated and may be idiopathic or linked to infections, lymphoma, or cold agglutinin disease. Drug-induced AIHA can occur through different immune mechanisms, including antibodies directed against RBC antigens (e.g., methyldopa), antibodies against an RBC–drug complex (hapten type, e.g., penicillin), or immune complex mechanisms (e.g., quinidine).
The differential diagnosis includes non-immune causes of hemolysis such as microangiopathic hemolytic anemia (e.g., TTP/HUS), hypersplenism, prosthetic valve hemolysis, infections, toxins, and inherited causes such as membrane disorders (e.g., hereditary spherocytosis), hemoglobinopathies, and enzyme deficiencies (e.g., G6PD). Chronic lymphocytic leukemia (CLL) can cause a positive direct antiglobulin test (DAT) without true AIHA, so labs and clinical evidence of hemolysis are important.
Evaluation focuses on confirming hemolysis and establishing immune causation. Typical hemolysis findings include reticulocytosis (or reticulocytopenia if marrow suppression is present), low haptoglobin, elevated indirect bilirubin, and elevated LDH. Initial tests include CBC, reticulocyte count, bilirubin/LDH, and a peripheral smear (spherocytes are typical in warm AIHA). The key diagnostic test is the direct antiglobulin test (DAT/Coombs), performed initially with a polyspecific reagent to detect IgG and/or complement on RBCs. A positive DAT supports AIHA: IgG ± C3d suggests warm AIHA, while C3d alone suggests cold AIHA. Additional evaluation may include hepatitis serologies, HIV testing, ANA, urine testing for hemoglobinuria/hemosiderinuria, and imaging (such as CT chest/abdomen/pelvis) if an underlying lymphoproliferative disorder is suspected.
Management includes stopping any offending drug when drug-induced disease is possible. Severe, life-threatening cases may rarely require plasmapheresis or exchange transfusion. Patients with cold antibody AIHA should avoid cold exposure. Warm AIHA is typically treated first with prednisone 1 to 2 mg/kg/day, with tapering after response. Some evidence supports upfront combination therapy with steroids plus rituximab to improve outcomes and durability of response. For relapse or steroid-refractory disease, rituximab is commonly used and has high response rates, with a substantial portion maintaining remission years later. Splenectomy is now usually reserved for cases refractory to both steroids and rituximab, and further options include immunosuppressive agents such as mycophenolate, cyclosporine, cyclophosphamide, IVIG, and sometimes danazol as an adjunct.
Cold AIHA generally responds poorly to corticosteroids, and treating underlying infection or lymphoproliferative disease is important. In primary cold agglutinin disease, rituximab-based regimens (often with bendamustine in fit patients) are commonly used, while rituximab alone may be used in older or frailer patients. IVIG or plasmapheresis can be used temporarily in severe cases while waiting for a durable therapy to work. Complement-directed therapies may be considered in severe disease; sutimlimab (targeting C1s) has been shown to rapidly reduce hemolysis and improve hemoglobin and fatigue in cold agglutinin disease. Splenectomy is generally ineffective in cold AIHA because clearance occurs mainly in the liver.
Prognosis is generally good unless AIHA is driven by a serious underlying condition such as leukemia or myeloma. Hematology referral is recommended for all AIHA cases, and surgical referral may be needed if splenectomy is being considered for refractory warm AIHA.
Autoimmune hemolytic anemia (AIHA) is a condition in which autoantibodies and/or complement bind to red blood cells (RBCs), leading to their premature destruction. About half of cases are primary (idiopathic), while the rest are secondary to underlying diseases or drugs. AIHA is commonly categorized into warm antibody–mediated disease (usually IgG, reacting best at 37°C), cold antibody–mediated disease (typically IgM with complement), and drug-induced immune hemolysis.
AIHA is uncommon, with an annual incidence of about 1 to 3 cases per 100,000 people and an estimated mortality around 10%. It is reported more often in women younger than 50 years. Patients most commonly present with fatigue and dyspnea. Pallor and jaundice may be present, and tachycardia with a flow murmur can occur when anemia is significant. Intravascular hemolysis may cause dark urine and back pain. Hepatomegaly or lymphadenopathy suggests a lymphoproliferative disorder or malignancy, while splenomegaly may suggest hypersplenism. The course is often chronic with relapses.
Warm AIHA is usually mediated by IgG antibodies and may be idiopathic or associated with leukemia/lymphoma, thymoma, myeloma, viral infections, babesiosis, and collagen-vascular diseases. Cold AIHA is commonly IgM- and complement-mediated and may be idiopathic or linked to infections, lymphoma, or cold agglutinin disease. Drug-induced AIHA can occur through different immune mechanisms, including antibodies directed against RBC antigens (e.g., methyldopa), antibodies against an RBC–drug complex (hapten type, e.g., penicillin), or immune complex mechanisms (e.g., quinidine).
The differential diagnosis includes non-immune causes of hemolysis such as microangiopathic hemolytic anemia (e.g., TTP/HUS), hypersplenism, prosthetic valve hemolysis, infections, toxins, and inherited causes such as membrane disorders (e.g., hereditary spherocytosis), hemoglobinopathies, and enzyme deficiencies (e.g., G6PD). Chronic lymphocytic leukemia (CLL) can cause a positive direct antiglobulin test (DAT) without true AIHA, so labs and clinical evidence of hemolysis are important.
Evaluation focuses on confirming hemolysis and establishing immune causation. Typical hemolysis findings include reticulocytosis (or reticulocytopenia if marrow suppression is present), low haptoglobin, elevated indirect bilirubin, and elevated LDH. Initial tests include CBC, reticulocyte count, bilirubin/LDH, and a peripheral smear (spherocytes are typical in warm AIHA). The key diagnostic test is the direct antiglobulin test (DAT/Coombs), performed initially with a polyspecific reagent to detect IgG and/or complement on RBCs. A positive DAT supports AIHA: IgG ± C3d suggests warm AIHA, while C3d alone suggests cold AIHA. Additional evaluation may include hepatitis serologies, HIV testing, ANA, urine testing for hemoglobinuria/hemosiderinuria, and imaging (such as CT chest/abdomen/pelvis) if an underlying lymphoproliferative disorder is suspected.
Management includes stopping any offending drug when drug-induced disease is possible. Severe, life-threatening cases may rarely require plasmapheresis or exchange transfusion. Patients with cold antibody AIHA should avoid cold exposure. Warm AIHA is typically treated first with prednisone 1 to 2 mg/kg/day, with tapering after response. Some evidence supports upfront combination therapy with steroids plus rituximab to improve outcomes and durability of response. For relapse or steroid-refractory disease, rituximab is commonly used and has high response rates, with a substantial portion maintaining remission years later. Splenectomy is now usually reserved for cases refractory to both steroids and rituximab, and further options include immunosuppressive agents such as mycophenolate, cyclosporine, cyclophosphamide, IVIG, and sometimes danazol as an adjunct.
Cold AIHA generally responds poorly to corticosteroids, and treating underlying infection or lymphoproliferative disease is important. In primary cold agglutinin disease, rituximab-based regimens (often with bendamustine in fit patients) are commonly used, while rituximab alone may be used in older or frailer patients. IVIG or plasmapheresis can be used temporarily in severe cases while waiting for a durable therapy to work. Complement-directed therapies may be considered in severe disease; sutimlimab (targeting C1s) has been shown to rapidly reduce hemolysis and improve hemoglobin and fatigue in cold agglutinin disease. Splenectomy is generally ineffective in cold AIHA because clearance occurs mainly in the liver.
Prognosis is generally good unless AIHA is driven by a serious underlying condition such as leukemia or myeloma. Hematology referral is recommended for all AIHA cases, and surgical referral may be needed if splenectomy is being considered for refractory warm AIHA.
0 Comments
